Option Care Health, Inc. (OPCH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 9/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 8.24% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Option Care stock surges on McKesson's home-infusion bet
- Strength Seen in Option Care (OPCH): Can Its 32.7% Jump Turn into More Strength?
- Option Care Health (OPCH) Rockets as CD&R, McKesson Table 37% Premium Bid
- Why Option Care Health Stock Skyrocketed on Tuesday
- McKesson, CD&R to Buy Option Care Health in $5.8 Billion Deal
- Option Care Health Agrees to $5.8 Billion Acquisition by CD&R and McKesson at $32.05 Per Share
- Google, Constellation Energy Deal; SpaceX Rises on Talks with NASA | Stock Movers
- Report of Possible $5 Billion Takeover Bid Sends Option Care Health Stock Surging
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Option Care Health, Inc..
Full OPCH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.